<?xml version='1.0' encoding='utf-8'?>
<document id="29318651"><sentence text="Effect of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide."><entity charOffset="14-25" id="DDI-PubMed.29318651.s1.e0" text="angiotensin" /><entity charOffset="56-66" id="DDI-PubMed.29318651.s1.e1" text="sacubitril" /><entity charOffset="67-76" id="DDI-PubMed.29318651.s1.e2" text="valsartan" /><entity charOffset="142-152" id="DDI-PubMed.29318651.s1.e3" text="furosemide" /><pair ddi="false" e1="DDI-PubMed.29318651.s1.e0" e2="DDI-PubMed.29318651.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29318651.s1.e0" e2="DDI-PubMed.29318651.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29318651.s1.e0" e2="DDI-PubMed.29318651.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29318651.s1.e0" e2="DDI-PubMed.29318651.s1.e3" /><pair ddi="false" e1="DDI-PubMed.29318651.s1.e1" e2="DDI-PubMed.29318651.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29318651.s1.e1" e2="DDI-PubMed.29318651.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29318651.s1.e1" e2="DDI-PubMed.29318651.s1.e3" /><pair ddi="false" e1="DDI-PubMed.29318651.s1.e2" e2="DDI-PubMed.29318651.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29318651.s1.e2" e2="DDI-PubMed.29318651.s1.e3" /></sentence><sentence text="Sacubitril/valsartan is indicated for the treatment of heart failure and reduced ejection fraction (HFrEF)"><entity charOffset="0-10" id="DDI-PubMed.29318651.s2.e0" text="Sacubitril" /><entity charOffset="11-20" id="DDI-PubMed.29318651.s2.e1" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.29318651.s2.e0" e2="DDI-PubMed.29318651.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29318651.s2.e0" e2="DDI-PubMed.29318651.s2.e1" /></sentence><sentence text=" Furosemide, a loop diuretic commonly used for the treatment of HFrEF, may be coadministered with sacubitril/valsartan in clinical practice"><entity charOffset="1-11" id="DDI-PubMed.29318651.s3.e0" text="Furosemide" /><entity charOffset="98-108" id="DDI-PubMed.29318651.s3.e1" text="sacubitril" /><entity charOffset="109-118" id="DDI-PubMed.29318651.s3.e2" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.29318651.s3.e0" e2="DDI-PubMed.29318651.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29318651.s3.e0" e2="DDI-PubMed.29318651.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29318651.s3.e0" e2="DDI-PubMed.29318651.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29318651.s3.e1" e2="DDI-PubMed.29318651.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29318651.s3.e1" e2="DDI-PubMed.29318651.s3.e2" /></sentence><sentence text=" The effect of sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of furosemide was evaluated in this open label, two-period, single-sequence study in healthy subjects"><entity charOffset="15-25" id="DDI-PubMed.29318651.s4.e0" text="sacubitril" /><entity charOffset="26-35" id="DDI-PubMed.29318651.s4.e1" text="valsartan" /><entity charOffset="84-94" id="DDI-PubMed.29318651.s4.e2" text="furosemide" /><pair ddi="false" e1="DDI-PubMed.29318651.s4.e0" e2="DDI-PubMed.29318651.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29318651.s4.e0" e2="DDI-PubMed.29318651.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29318651.s4.e0" e2="DDI-PubMed.29318651.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29318651.s4.e1" e2="DDI-PubMed.29318651.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29318651.s4.e1" e2="DDI-PubMed.29318651.s4.e2" /></sentence><sentence text="" /><sentence text="All subjects (n = 28) received 40 mg oral single-dose furosemide during period 1, followed by a washout of 2 days"><entity charOffset="54-64" id="DDI-PubMed.29318651.s6.e0" text="furosemide" /></sentence><sentence text=" In period 2, sacubitril/valsartan 200 mg (97/103 mg) was administered twice daily for 5 days and a single dose of 40 mg furosemide was coadministered on day 6"><entity charOffset="25-34" id="DDI-PubMed.29318651.s7.e0" text="valsartan" /><entity charOffset="121-131" id="DDI-PubMed.29318651.s7.e1" text="furosemide" /><pair ddi="false" e1="DDI-PubMed.29318651.s7.e0" e2="DDI-PubMed.29318651.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29318651.s7.e0" e2="DDI-PubMed.29318651.s7.e1" /></sentence><sentence text=" Serial plasma and urine samples were collected to determine the pharmacokinetics of furosemide and sacubitril/valsartan and the pharmacodynamics of furosemide"><entity charOffset="85-95" id="DDI-PubMed.29318651.s8.e0" text="furosemide" /><entity charOffset="100-110" id="DDI-PubMed.29318651.s8.e1" text="sacubitril" /><entity charOffset="111-120" id="DDI-PubMed.29318651.s8.e2" text="valsartan" /><entity charOffset="149-159" id="DDI-PubMed.29318651.s8.e3" text="furosemide" /><pair ddi="false" e1="DDI-PubMed.29318651.s8.e0" e2="DDI-PubMed.29318651.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29318651.s8.e0" e2="DDI-PubMed.29318651.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29318651.s8.e0" e2="DDI-PubMed.29318651.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29318651.s8.e0" e2="DDI-PubMed.29318651.s8.e3" /><pair ddi="false" e1="DDI-PubMed.29318651.s8.e1" e2="DDI-PubMed.29318651.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29318651.s8.e1" e2="DDI-PubMed.29318651.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29318651.s8.e1" e2="DDI-PubMed.29318651.s8.e3" /><pair ddi="false" e1="DDI-PubMed.29318651.s8.e2" e2="DDI-PubMed.29318651.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29318651.s8.e2" e2="DDI-PubMed.29318651.s8.e3" /></sentence><sentence text=" The point estimates and the associated 90% confidence intervals for pharmacokinetic parameters were evaluated" /><sentence text="" /><sentence text="Coadministration of furosemide with sacubitril/valsartan decreased the maximum observed plasma concentration (Cmax ) [estimated geometric mean ratio (90% confidence interval): 0"><entity charOffset="20-30" id="DDI-PubMed.29318651.s11.e0" text="furosemide" /><entity charOffset="36-46" id="DDI-PubMed.29318651.s11.e1" text="sacubitril" /><entity charOffset="47-56" id="DDI-PubMed.29318651.s11.e2" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.29318651.s11.e0" e2="DDI-PubMed.29318651.s11.e0" /><pair ddi="false" e1="DDI-PubMed.29318651.s11.e0" e2="DDI-PubMed.29318651.s11.e1" /><pair ddi="false" e1="DDI-PubMed.29318651.s11.e0" e2="DDI-PubMed.29318651.s11.e2" /><pair ddi="false" e1="DDI-PubMed.29318651.s11.e1" e2="DDI-PubMed.29318651.s11.e1" /><pair ddi="false" e1="DDI-PubMed.29318651.s11.e1" e2="DDI-PubMed.29318651.s11.e2" /></sentence><sentence text="50 (0" /><sentence text="44, 0" /><sentence text="56)], area under the plasma concentration-time curve (AUC) from time 0 to infinity [0" /><sentence text="72 (0" /><sentence text="67, 0" /><sentence text="77)] and 24-h urinary excretion of furosemide [0"><entity charOffset="35-45" id="DDI-PubMed.29318651.s17.e0" text="furosemide" /></sentence><sentence text="74 (0" /><sentence text="69, 0" /><sentence text="79)]" /><sentence text=" When coadministered with sacubitril/valsartan, 0-4-h, 4-8-h and 0-24-h diuresis in response to furosemide was reduced by ~7%, 21% and 0"><entity charOffset="26-36" id="DDI-PubMed.29318651.s21.e0" text="sacubitril" /><entity charOffset="37-46" id="DDI-PubMed.29318651.s21.e1" text="valsartan" /><entity charOffset="96-106" id="DDI-PubMed.29318651.s21.e2" text="furosemide" /><pair ddi="false" e1="DDI-PubMed.29318651.s21.e0" e2="DDI-PubMed.29318651.s21.e0" /><pair ddi="false" e1="DDI-PubMed.29318651.s21.e0" e2="DDI-PubMed.29318651.s21.e1" /><pair ddi="false" e1="DDI-PubMed.29318651.s21.e0" e2="DDI-PubMed.29318651.s21.e2" /><pair ddi="false" e1="DDI-PubMed.29318651.s21.e1" e2="DDI-PubMed.29318651.s21.e1" /><pair ddi="false" e1="DDI-PubMed.29318651.s21.e1" e2="DDI-PubMed.29318651.s21.e2" /></sentence><sentence text="2%, respectively, while natriuresis was reduced by ~ 28" /><sentence text="5%, 7% and 15%, respectively" /><sentence text=" Post hoc analysis of the pivotal phase III Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) indicated that the median furosemide dose was similar at baseline and at the end of the study in the sacubitril/valsartan group"><entity charOffset="202-212" id="DDI-PubMed.29318651.s24.e0" text="furosemide" /><entity charOffset="277-287" id="DDI-PubMed.29318651.s24.e1" text="sacubitril" /><entity charOffset="288-297" id="DDI-PubMed.29318651.s24.e2" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.29318651.s24.e0" e2="DDI-PubMed.29318651.s24.e0" /><pair ddi="false" e1="DDI-PubMed.29318651.s24.e0" e2="DDI-PubMed.29318651.s24.e1" /><pair ddi="false" e1="DDI-PubMed.29318651.s24.e0" e2="DDI-PubMed.29318651.s24.e2" /><pair ddi="false" e1="DDI-PubMed.29318651.s24.e1" e2="DDI-PubMed.29318651.s24.e1" /><pair ddi="false" e1="DDI-PubMed.29318651.s24.e1" e2="DDI-PubMed.29318651.s24.e2" /></sentence><sentence text="" /><sentence text="Sacubitril/valsartan reduced plasma Cmax and AUC and 24-h urinary excretion of furosemide, while not significantly affecting its pharmacodynamic effects in healthy subjects"><entity charOffset="0-10" id="DDI-PubMed.29318651.s26.e0" text="Sacubitril" /><entity charOffset="11-20" id="DDI-PubMed.29318651.s26.e1" text="valsartan" /><entity charOffset="79-89" id="DDI-PubMed.29318651.s26.e2" text="furosemide" /><pair ddi="false" e1="DDI-PubMed.29318651.s26.e0" e2="DDI-PubMed.29318651.s26.e0" /><pair ddi="false" e1="DDI-PubMed.29318651.s26.e0" e2="DDI-PubMed.29318651.s26.e1" /><pair ddi="false" e1="DDI-PubMed.29318651.s26.e0" e2="DDI-PubMed.29318651.s26.e2" /><pair ddi="false" e1="DDI-PubMed.29318651.s26.e1" e2="DDI-PubMed.29318651.s26.e1" /><pair ddi="false" e1="DDI-PubMed.29318651.s26.e1" e2="DDI-PubMed.29318651.s26.e2" /></sentence><sentence text="" /></document>